Park, Jongmin http://orcid.org/0000-0001-8338-9346
Park, Jun Seok
Huang, Chen-Han
Jo, Ala
Cook, Kaitlyn http://orcid.org/0000-0003-3794-3312
Wang, Rui http://orcid.org/0000-0001-5007-193X
Lin, Hsing-Ying
Van Deun, Jan
Li, Huiyan
Min, Jouha http://orcid.org/0000-0002-6737-7254
Wang, Lan
Yoon, Ghilsuk
Carter, Bob S.
Balaj, Leonora http://orcid.org/0000-0003-0931-9715
Choi, Gyu-Seog
Castro, Cesar M.
Weissleder, Ralph http://orcid.org/0000-0003-0828-4143
Lee, Hakho http://orcid.org/0000-0002-0087-0909
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2020R1A4A1016093, 2016R1D1A1B03930709)
Massachusetts General Hospital (Fund for Medical Discovery Fellowship, Scholar fund)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA204019, U01CA233360, R01CA229777, R01CA204019)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R21DA049577)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (DOD-W81XWH1910199, DOD-W81XWH1910194)
Article History
Received: 21 November 2019
Accepted: 18 May 2021
First Online: 28 June 2021
Competing interests
: The authors declare the filing of a patent (US20190346434A1) that was assigned to and handled by Massachusetts General Hospital. The following disclosures are not related to the subject matter of this work. R.Weissleder is a consultant to ModeRNA, Tarveda Pharmaceuticals, Lumicell, Seer, Earli, Alivio Therapeutics, Aikili Biosystems and Accure Health. H. Lee is a consultant to Exosome Diagnostics, Accure Health and Aikili Biosystems.